MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
fundraising activities
$4,514,482
Proceeds from issuance of
common stock for cash
$1,218,241
Net increase
(decrease) in cash
-$2,467,115
Net cash provided by
financing activities
$5,732,723
Net increase
(decrease) in cash
-$2,467,115
Canceled cashflow
$5,732,723
Changes in fair value of
digital assets
-$995,161
Fair value of vested
advisory warrant
$665,030
Stock compensation
expense
$329,409
Increase/(decrease) in accounts
payable and accrued...
$113,287
Amortization of right of use
assets
$113,249
Depreciation and
amortization
$44,045
Net cash used in
operating activities
-$5,182,558
Canceled cashflow
$2,260,181
Net cash used in
investing activities
-$3,017,280
Net loss
-$7,027,410
Changes in fair value of
warrant liability
-$319,537
Decrease in lease
liability
-$89,252
Digital asset staking
compensation
$5,121
Decrease/(increase) in prepaid
expenses
$1,419
Purchase of digital
intangible assets
$3,000,000
Purchases of fixed assets
$17,280
Back
Back
Cash Flow
source: myfinsight.com
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)